Acemetacine, anticoagulants
Acemetacine may enhance the effects of anti-coagulant.
Acetazolamide, oral anticoagulants
Possible potentiation of the effects of oral anti-coagulant
Acetylsalicylic acid [1], oral anticoagulants ---> SmPC of [1] of eMC
Increased risk of bleeding due to inhibited thrombocyte function, injury of the duodenal mucosa and displacement of oral anticoagulants from their plasma protein binding sites. The bleeding time should be monitored
Adrenaline, anticoagulants
The tendency to bleed is increased during the treatment with anticoagulants and adrenaline
Afamelanotide [1], anticoagulants ---> SmPC of [1] of EMA
Patients taking substances which reduce coagulation, acetylsalicylic acid and non-steroidal anti-inflammatory drug (NSAIDs) may experience increased bruising or bleeding at the site of implantation.
Alcohol, oral anticoagulants
The acute/chronic alcohol intake enhances/decreases the anticoagulant effect
Alipogene tiparvovec [1], anticoagulants ---> SmPC of [1] of EMA
Anti-platelet or other anti-coagulant medicinal products must not be used concomitantly with alipogen at the time of injection.
Alprostadil [1], anticoagulants ---> SmPC of [1] of eMC
Alprostadil may enhance the effects of anticoagulants
Alteplase [1], oral anticoagulants ---> SmPC of [1] of eMC
Increased risk of haemorrhage
Aminoglycoside antibiotics, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Aminomethylbenzoic acid, anticoagulants
The co-administration may weaken the effect of antifibrinolytic agent
Ampicillin, anticoagulants
The changes in the platelet aggregation and prothrombin time caused by parenteral administered penicillins can be enhanced with the co-administration of anticoagulants
Ampicillin/sulbactam, anticoagulants
The changes in the platelet aggregation and prothrombin time caused by parenteral administered penicillins can be enhanced with the co-administration of anticoagulants
Amprenavir [1], oral anticoagulants ---> SmPC of [1] of EMA
A reinforced monitoring of the International Normalised Ratio is recommended in case of administration of Amprenavir with warfarin or other oral anticoagulants, due to a possible decrease or increase of their antithrombotic effect
Anabolic steroids, oral anticoagulants
Anabolic steroids have been reported to increase the activity of oral anticoagulants.
Androgens, oral anticoagulants
The androgen may enhance the anticoagulant effect and increase the bleeding risk
Antibiotics, anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Antibiotics, oral anticoagulants
The co-administration may increase the anticoagulant activity and increase the bleeding risk
Antibiotics, oral anticoagulants
It is recommended that the INR should be monitored as appropriate during and shortly after co-administration of antibiotics with oral anti-coagulant medicinal products.
Antibiotics, oral anticoagulants ---> SmPC of [meropenem/vaborbactam] of EMA
There have been many reports of increases in the anticoagulant effects of orally administered anticoagulants, including warfarin in patients, who are concomitantly receiving antibacterial agents.
Anticoagulants, anticoagulants
The co-administration may increase the anticoagulant and bleeding risk effect
Anticoagulants, antifibrinolytics
The co-administration may weaken the effect of antifibrinolytic agent
Anticoagulants, antihemorrhagics
The co-administration may decrease or abolish the anticoagulant effect
Anticoagulants, antineoplastics
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, argatroban [2] ---> SmPC of [2] of eMC
Concomitant use of argatroban with other anticoagulants may increase the risk of bleeding.
Anticoagulants, articaine/epinephrine
There is an increase in the tendency to bleed during the treatment with anticoagulant medicinal products
Anticoagulants, asparaginase [2] ---> SmPC of [2] of EMA
Concomitant use of glucocorticoids and/ or anticoagulants with asparaginase may increase the risk of a change in coagulation parameters (see section 4.4). This can promote tendency to bleeding (anticoagulants) or thrombosis (glucocorticoids).
Anticoagulants, bemiparin
The concomitant administration of bemiparin and anticoagulants is not advisable. Increased risk of bleeding.
Anticoagulants, benperidol
The co-treatment of benperidol injection with anticoagulants agents is contraindicated
Anticoagulants, benzylpenicillin
Carefully control of the prothrombin time
Anticoagulants, bivalirudin [2] ---> SmPC of [2] of EMA
Combined use of anti-coagulant medicinal products can be expected to increase the risk of bleeding.
Anticoagulants, botulinum toxin type B [2] ---> SmPC of [2] of EMA
Caution should be used in patients with bleeding disorders or receiving anticoagulant therapy.
Anticoagulants, bromelain
The co-administration is contraindicated
Anticoagulants, bromperidol
Regular monitoring of the coagulation status is recommended
Anticoagulants, bupivacaine [2] ---> SmPC of [2] of eMC
Epidural anaesthesia is contra-indicated in patients receiving anticoagulant therapy.
Anticoagulants, cefadroxil
Frequent checks on coagulation parameters are necessary during concomitant long-term use of cefadroxil and anticoagulants to avoid haemorrhagic complications.
Anticoagulants, chlorprothixene
Regular monitoring of the coagulation status is recommended
Anticoagulants, chlortetracycline
Chlortetracycline increases the anticoagulant effect
Anticoagulants, cilostazol [2] ---> SmPC of [2] of EMA
Caution is advised in patients receiving both cilostazol and any anticoagulant agent and is contraindicated with 2 or more additional antiplatelet/anticoagulant agents
Anticoagulants, citalopram [2] ---> SmPC of [2] of eMC
Caution is warranted for patients who are being treated simultaneously with anticoagulants, medicinal products that affect platelet function, or other medicines that can increase the risk of haemorrhage
Anticoagulants, codergocrin
The combination may increase the risk of bleeding. Codergocrin decreases also the blood viscosity
Anticoagulants, colchicine
The co-administration may decrease the effect of colchicine and/or increase its toxicity
Anticoagulants, corticosteroids ---> SmPC of [deflazacort] of eMC
Corticosteroids may increase or decrease the effects of anticoagulant drugs
Anticoagulants, cytostatics
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, dabigatran etexilate
Concomitant treatment of dabigatran with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter
Anticoagulants, dabigatran [2] ---> SmPC of [2] of EMA
The co-administration may increase the risk of bleeding
Anticoagulants, dalteparin [2] ---> SmPC of [2] of eMC
Enhancement of the anticoagulant effect of dalteparin by anticoagulant/antiplatelet agents
Anticoagulants, dapoxetine [2] ---> SmPC of [2] of eMC
There have been reports of bleeding abnormalities with SSRIs. Caution is advised in patients taking dapoxetine, particularly in concomitant use anticoagulants (e.g., warfarin)
Anticoagulants, deferasirox [2] ---> SmPC of [2] of EMA
The concomitant administration of deferasirox with anticoagulants may increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is required when deferasirox is combined with these substances.
Anticoagulants, deflazacort
Corticosteroids may increase or decrease the effects of anticoagulant drugs
Anticoagulants, dexibuprofen [2] ---> SmPC of [2] of eMC
The effects of anticoagulants on bleeding time can be potentiated by NSAIDs.
Anticoagulants, diclofenac
Caution is recommended as concomitant use may increase bleeding risk
Anticoagulants, dihydroergotoxine
The combination may increase the risk of bleeding. Dihydroergotoxine decreases also the blood viscosity
Anticoagulants, dipyridamole [2] ---> SmPC of [2] of eMC
When dipyridamole is used in combination with any substances impacting coagulation such as anticoagulants and antiplatelets the safety profile for these medications must be observed.
Anticoagulants, edoxaban [2] ---> SmPC of [2] of EMA
Co-administration of edoxaban with other anticoagulants is contraindicated due to increased risk of bleeding
Anticoagulants, enoxaparin sodium [2] ---> SmPC of [2] of EMA
It is recommended that agents which affect haemostasis should be discontinued prior to enoxaparin therapy unless their use is essential.
Anticoagulants, epoprostenol [2] ---> SmPC of [2] of eMC
When epoprostenol is administered to patients receiving concomitant anticoagulants standard anticoagulant monitoring is advisable as there may be potentiation of effect.
Anticoagulants, escin
Aescin may enhance the effect of the anticoagulant
Anticoagulants, fibrates
Increased effect of the anticoagulant
Anticoagulants, fluphenazine [2] ---> SmPC of [2] of eMC
Phenothiazines may impair the action of anti-convulsants.
Anticoagulants, flurbiprofen [2] ---> SmPC of [2] of eMC
NSAIDs may enhance the effects of anticoagulants such as warfarin
Anticoagulants, fosphenytoin [2] ---> SmPC of [2] of eMC
Blood levels and/or effects of anticoagulants (warfarin) may be altered by phenytoin
Anticoagulants, fotemustine
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, fulvestrant [2] ---> SmPC of [2] of EMA
Due to the intramuscular route of administration, fulvestrant should be used with caution if treating patients with bleeding diatheses, thrombocytopenia or those taking anticoagulant treatment.
Anticoagulants, gestagens ---> SmPC of [medroxyprogesterone] of eMC
It is possible a decrease in anticoagulant efficacy due to progestagens may affect the clotting factors
Anticoagulants, gliclazide [2] ---> SmPC of [2] of eMC
Sulphonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of the anticoagulant may be necessary.
Anticoagulants, GP IIb/IIIa inhibitors
Use the anticoagulant with caution with medicinal products which affect platelet function
Anticoagulants, haloperidol
It is recommended the regular control of coagulation status
Anticoagulants, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Anticoagulants, ibuprofen [2] ---> SmPC of [2] of EMA
Ibuprofen may increase the effect of anticoagulants and enhance the risk of bleeding.
Anticoagulants, ifosfamide
The co-administration may increase the risk of bleeding
Anticoagulants, iloprost [2] ---> SmPC of [2] of EMA
Since iloprost inhibits platelet function its use with anticoagulants or other inhibitors of platelet aggregation may increase the risk of bleeding. A careful monitoring of the patients is recommended.
Anticoagulants, imatinib [2] ---> SmPC of [2] of EMA
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
Anticoagulants, indometacin [2] ---> SmPC of [2] of eMC
Patients also receiving anticoagulants should be closely observed for alterations of the prothrombin time.
Anticoagulants, ipilimumab [2] ---> SmPC of [2] of EMA
Since gastrointestinal haemorrhage is an adverse reaction with ipilimumab, patients who require concomitant anticoagulant therapy should be monitored closely.
Anticoagulants, isradipine
Isradipine doesn't bind specifically to proteins; however, caution is recommended in combination with anticoagulants and anticonvulsants
Anticoagulants, ketoprofen [2] ---> SmPC of [2] of eMC
Increased risk of bleeding
Anticoagulants, ketorolac [2] ---> SmPC of [2] of eMC
Ketorolac is contraindicated in combination with anti-coagulants, such as warfarin since co-administration of NSAIDs and anti-coagulants may cause an enhanced anti-coagulant effect
Anticoagulants, ketotifen
Ketotifen may potentiate the effects of anticoagulants
Anticoagulants, lofepramine
Lofepramine may change the anticoagulant effect by inhibiting hepatic metabolism.
Anticoagulants, medroxyprogesterone
It is possible a decrease in anticoagulant efficacy due to progestagens may affect the clotting factors
Anticoagulants, metformin
Metformin potentiates the effect of anticoagulants.
Anticoagulants, methyldopa
The co-administration may enhance the anticoagulant effect and prolong the prothrombin time
Anticoagulants, nabumetone [2] ---> SmPC of [2] of eMC
NSAIDs may enhance the effects of anti-coagulants, such as warfarin; its concomitant administration with nabumetone should be undertaken with caution and overdose signals carefully monitored.
Anticoagulants, nicergoline
Nicergoline may enhance the effect of anticoagulant agent (decreased platelet aggregation and blood viscosity)
Anticoagulants, nicomorphine
Nicomorphine may enhance the effect of anticoagulant agent
Anticoagulants, nicotinic acid
Prothrombin time and platelet counts must be monitored closely
Anticoagulants, oxolamine
Possible prolongation of prothrombin time
Anticoagulants, padeliporfin [2] ---> SmPC of [2] of EMA
Anticoagulant medicinal products and those that decrease platelet aggregation (e.g. acetylsalicylic acid) should be stopped at least 10 days before the procedure with TOOKAD.
Anticoagulants, parecoxib [2] ---> SmPC of [2] of EMA
Anticoagulant therapy should be monitored, particularly during the first few days after initiating parecoxib therapy in patients receiving warfarin or other anticoagulants, since these patients have an increased risk of bleeding complications.
Anticoagulants, pegaspargase [2] ---> SmPC of [2] of EMA
The use of Oncaspar can lead to fluctuating coagulation factors. This can promote the tendency to bleeding and/or thrombosis. Caution is therefore needed when anticoagulants are given concomitantly.
Anticoagulants, pelargonium sidoides
Pelargonium sidoides may enhance the effect of anticoagulants. The combination is not recommended
Anticoagulants, penicillins
The changes in the platelet aggregation and prothrombin time caused by parenteral administered penicillins can be enhanced with the co-administration of anticoagulants
Anticoagulants, pentosan polysulfate
Mutual enhancement of anticoagulant effect
Anticoagulants, pentosan polysulfate sodium [2] ---> SmPC of [2] of EMA
Patients who are concomitantly treated should be evaluated for any haemorrhagic event in order to adapt the dose if needed
Anticoagulants, pentosan sulfate
Mutual enhancement of anticoagulant effect
Anticoagulants, perphenazine
Perphenazine may affect action of anticoagulants and increase the bleeding time
Anticoagulants, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may impair the action of anti-convulsants.
Anticoagulants, phenprocoumon
Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of other anticoagulant drugs
Anticoagulants, piroxicam [2] ---> SmPC of [2] of eMC
NSAIDs, including piroxicam, may enhance the effects of anticoagulants, such as warfarin. Therefore, the use of piroxicam with concomitant anticoagulant such as warfarin should be avoided.
Anticoagulants, platelet aggregation inhibitors
Use the anticoagulant with caution with medicinal products which affect platelet function
Anticoagulants, ponatinib [2] ---> SmPC of [2] of EMA
Concomitant use of ponatinib with anti-clotting agents should be approached with caution in patients who may be at risk of bleeding events. Formal studies of ponatinib with anti-clotting medicinal products have not been conducted.
Anticoagulants, primidone
Primidone may decrease the effect of anticoagulant drug
Anticoagulants, procaine
Enhancement of an existent haemorrhagic diathesis
Anticoagulants, prostacyclin analogues
Use the anticoagulant with caution with medicinal products which affect platelet function
Anticoagulants, proteolytic enzymes enriched in bromelain [2] ---> SmPC of [2] of EMA
Caution and monitoring is needed when prescribing concomitant medicinal products that affect coagulation.
Anticoagulants, regorafenib [2] ---> SmPC of [2] of EMA
Blood counts and coagulation parameters should be monitored in patients treated with anticoagulants (e.g. warfarin and phenprocoumon) or other concomitant medicinal products that increase the risk of bleeding.
Anticoagulants, rifabutin [2] ---> SmPC of [2] of eMC
Rifabutin has been shown to induce the enzymes of the cytochrome P450 3A subfamily and therefore may affect the pharmacokinetic behaviour of drugs metabolised by the enzymes belonging to this subfamily.
Anticoagulants, rivaroxaban [2] ---> SmPC of [2] of EMA
Concomitant treatment with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter.
Anticoagulants, secnidazole
Possible enhancement of anticoagulant effect
Anticoagulants, selegiline [2] ---> SmPC of [2] of eMC
In view of the high degree of binding to plasma proteins by selegiline particular attention must be given to patients who are being treated with medicines with a narrow therapeutic margin
Anticoagulants, sertraline [2] ---> SmPC of [2] of EMA
The risk of bleeding may be increased when medicines acting on platelet function or other medicines that might increase bleeding risk are concomitantly administered with SSRIs
Anticoagulants, SNRIs ---> SmPC of [sertraline] of EMA
The risk of bleeding may be increased when medicines acting on platelet function or other medicines that might increase bleeding risk are concomitantly administered with SSRIs
Anticoagulants, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Anticoagulants, sodium iodide
The withdrawal period prior to administration of sodium [131I]iodine is 1 week
Anticoagulants, streptokinase [2] ---> SmPC of [2] of eMC
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
Anticoagulants, streptokinase/streptodornase
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
Anticoagulants, sulfadiazine
The co-administration may enhance the anticoagulant effect and increase the bleeding risk. Special caution is recommended
Anticoagulants, sulfonylureas
Sulphonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of the anticoagulant may be necessary.
Anticoagulants, sunitinib [2] ---> SmPC of [2] of EMA
Periodic monitoring by complete blood counts (platelets), coagulation factors (PT/INR), and physical examination
Anticoagulants, tenecteplase [2] ---> SmPC of [2] of EMA
Medicinal products that affect coagulation or those that alter platelet function may increase the risk of bleeding prior to, during or after tenecteplase therapy.
Anticoagulants, testosterone [2] ---> SmPC of [2] of EMA
When testosterone is given concomitantly with anticoagulants, the anticoagulant effect may increase.
Anticoagulants, tetracyclines ---> SmPC of [doxycycline] of eMC
Tetracycline may decrease the plasma prothrombin time and increase the anticoagulant activity. A reduction of anti-coagulant doses may be required
Anticoagulants, thioridazine
The combination of anticoagulants with phenothiazines may decrease the prothrombin time, probably due to enzymatic competition, necessitating careful monitoring of plasma prothrombin time
Anticoagulants, thiotepa [2] ---> SmPC of [2] of EMA
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, tiaprofenic acid
It is considered unsafe to take NSAIDs in combination with anticoagulants due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
Anticoagulants, tibolone [2] ---> SmPC of [2] of eMC
Since tibolone may increase blood fibrinolytic activity, it may enhance the effect of anticoagulants. This effect has been demonstrated with warfarin.
Anticoagulants, tigecycline [2] ---> SmPC of [2] of EMA
Since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants
Anticoagulants, trapidil
Possible increase of anticoagulant effect
Anticoagulants, treprostinil
Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors, including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding.
Anticoagulants, triflusal
Triflusal enhances the effect of anticoagulant agent
Anticoagulants, venlafaxine
Possible prolongation of bleeding time. Caution is recommended
Anticoagulants, vinblastine
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, vincristine
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Anticoagulants, vindesine
Increased bleeding risk. More frequent controls of INR are recommended
Anticoagulants, vinorelbine [2] ---> SmPC of [2] of eMC
The eventuality of interaction between oral anticoagulants and anticancer chemotherapy require, if it is decided to treat the patient with oral anticoagulants, to increase frequency of the INR (International Normalised Ratio) monitoring.
Anticoagulants, zuclopenthixol [2] ---> SmPC of [2] of eMC
Zuclopenthixol may potentiate the effects of anticoagulants
Antidepressants with serotonergic effect, oral anticoagulants ---> SmPC of [vortioxetine] of EMA
Caution should be exercised when a serotonergic medicine is combined with oral anticoagulants due to a potential increased risk of bleeding
Antihistamines, oral anticoagulants
The antihistaminic agent may decrease the effect of oral anticoagulant
Antineoplastics, oral anticoagulants
The possible interaction between oral anticoagulants and antineoplastic agents requires more frequent monitoring of INR, if patients should be treated with oral anticoagulants
Apixaban [1], oral anticoagulants ---> SmPC of [1] of EMA
Due to an increased bleeding risk, concomitant treatment of apixaban with any other anticoagulants is contraindicated
Ascorbic acid, oral anticoagulants
The action of oral anticoagulant may be modified by the ascorbic acid
Azapropazone, oral anticoagulants
Significant increase of anticoagulant effect. The co-administration is contraindicated
Azole antifungals, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Barbiturates, oral anticoagulants
Barbiturate, enzymatic inductor, may increase the metabolism of the oral anticoagulant and decrease its plasma levels and effect
Beta-lactam antibiotics, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Bisacodyl, oral anticoagulants
The co-administration may decrease the absorption of the oral anticoagulant agent
Bumadizone, oral anticoagulants
It is recommended a regular control of the prothrombin time
Carbamazepine [1], oral anticoagulants ---> SmPC of [1] of eMC
Carbamazepine may lower the plasma level of oral anticoagulant
Carbimazole, oral anticoagulants
Since carbimazole is a vitamin K antagonist, the effect of anticoagulants could be intensified.
Carboplatin, oral anticoagulants
The possible interaction between oral anticoagulants and antineoplastic agents requires more frequent monitoring of INR, if patients should be treated with oral anticoagulants
Cefaclor [1], oral anticoagulants ---> SmPC of [1] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cefadroxil, oral anticoagulants [2] ---> SmPC of [2] of eMC
Frequent checks on coagulation parameters are necessary during concomitant long-term use of cefadroxil and anticoagulants to avoid haemorrhagic complications.
Cefazolin, oral anticoagulants
The coagulation parameters should be controlled regularly in the concomitant use of cefazolin and drugs affecting coagulation
Cefepime, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cefixime, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cefotaxime, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cefpodoxime, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Ceftazidime, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Ceftibuten, oral anticoagulants
Cephalosporins may affect the prothrombin activity and prolong the prothrombin time
Ceftriaxone, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cefuroxime [1], oral anticoagulants ---> SmPC of [1] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Celecoxib [1], oral anticoagulants ---> SmPC of [1] of EMA
Anticoagulant activity should be monitored in patients taking warfarin or other anticoagulants
Cephalexin, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cephalosporins, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Certoparin, oral anticoagulants
The co-administration may enhance the pharmacological effects of certoparin
Chloramphenicol, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Cholestyramine, oral anticoagulants
Cholestyramine may partially abolish the absorption of the co-administered medicament
Cimetidine, oral anticoagulants
Enhancement of anticoagulant effect
Cisapride, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Cisplatin [1], oral anticoagulants ---> SmPC of [1] of eMC
In the event of simultaneous use of oral anticoagulants, it is advisable to regularly check the INR.
Clarithromycin, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Clopidogrel [1], oral anticoagulants ---> SmPC of [1] of EMA
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings
Clopidogrel/acetylsalicylic acid [1], oral anticoagulants ---> SmPC of [1] of EMA
The co-administration is not recommended since it may increase the intensity of bleedings
Cloxacillin, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Combination oral contraceptives, oral anticoagulants ---> SmPC of [ethinylestradiol/gestodene] of eMC
Oral contraceptives may decrease the effect of oral anticoagulants probably due to an antagonist effect on some coagulation factors
Corticosteroids, oral anticoagulants ---> SmPC of [triamcinolone acetonide] of eMC
Corticosteroids may potentiate or decrease anticoagulant action. Patients receiving oral anticoagulants and corticosteroids should therefore be closely monitored.
Cotrimoxazole, oral anticoagulants ---> SmPC of [moxifloxacin] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Coxibs, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Cyproterone/ethinylestradiol, oral anticoagulants
Oral contraceptives may decrease the effect of oral anticoagulants probably due to an antagonist effect on some coagulation factors
Cytostatics, oral anticoagulants
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Cytotoxic agents, oral anticoagulants
Patients treated with anticoagulant should be monitored more frequently
Dabigatran etexilate [1], oral anticoagulants ---> SmPC of [1] of EMA
Concomitant treatment of dabigatran with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter
Dabigatran [1], oral anticoagulants ---> SmPC of [1] of EMA
The co-administration may increase the risk of bleeding
Dexchlorpheniramine, oral anticoagulants
The antihistaminic agent may decrease the effect of oral anticoagulant
Dexrazoxane [1], oral anticoagulants ---> SmPC of [1] of EMA
Patients treated with anticoagulants should be monitored more frequently as cytotoxic agents may interact with oral anticoagulants.
Disulfiram, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Diuretics, oral anticoagulants
The co-administration may decrease the anticoagulant effect
Drotrecogin alfa [1], oral anticoagulants ---> SmPC of [1] of EMA
Caution should be employed when using drotrecogin alfa with other drugs that affect haemostasis
Duloxetine [1], oral anticoagulants ---> SmPC of [1] of EMA
Caution should be exercised when duloxetine is combined with oral anticoagulants or antiplatelet agents due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction.
Econazole, oral anticoagulants [2] ---> SmPC of [2] of eMC
Patients taking oral anticoagulants, such as warfarin or acenocoumarol, caution should be exercised and the anticoagulant effect should be monitored more frequently.
Enoxacin, oral anticoagulants
Increased effect of anticoagulant agent and the risk of bleeding
Enoxaparin [1], oral anticoagulants ---> SmPC of [1] of eMC
The co-administration may enhance the pharmacologic effect and increase the bleeding risk. A close clinical and laboratory monitoring is recommended
Erythromycin, oral anticoagulants
Concomitant use of erythromycin with oral anticoagulants increases the anticoagulant effect
Escitalopram [1], oral anticoagulants ---> SmPC of [1] of eMC
Altered anticoagulant effects may occur when escitalopram is combined with oral anticoagulants.
Ethinyl estradiol, oral anticoagulants [2] ---> SmPC of [2] of eMC
Ethinylestradiol may reduce the effects of anticoagulants
Etoposide, oral anticoagulants
Etoposide may displace coumarine from its plasma protein binding and increase the anticoagulant effect
Etoricoxib [1], oral anticoagulants ---> SmPC of [1] of eMC
Patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with etoricoxib is initiated or the dose of etoricoxib is changed
Fenofibrate, oral anticoagulants ---> SmPC of [fenofibrate/pravastatine] of EMA
Fenofibrate enhances oral anticoagulant effect and may increase risk of bleeding. The coadministration is not recommended
Fibrates, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Flecainide [1], oral anticoagulants ---> SmPC of [1] of eMC
The treatment with flecainide is compatible with the use of oral anticoagulants
Fludrocortisone, oral anticoagulants [2] ---> SmPC of [2] of eMC
Corticosteroids may potentiate or decrease anticoagulant action.
Fluorouracil, oral anticoagulants
Fluorouracil may increase the anticoagulant effect
Fluoxetine [1], oral anticoagulants ---> SmPC of [1] of eMC
Altered anti-coagulant effects (laboratory values and/or clinical signs and symptoms), with no consistent pattern, but including increased bleeding, have been reported uncommonly when fluoxetine is co-administered with oral anticoagulants.
Flutamide, oral anticoagulants
In concomitant use with oral anticoagulants have been reported increases in prothrombin time after beginning the treatment with flutamide
Fluvoxamine [1], oral anticoagulants ---> SmPC of [1] of eMC
In patients on oral anticoagulants and fluvoxamine, the risk for haemorrhage may increase and these patients should therefore be closely monitored.
Fosamprenavir/ritonavir, oral anticoagulants ---> SmPC of [fosamprenavir] of EMA
A reinforced monitoring of the International Normalised Ratio is recommended in case of administration of Amprenavir with warfarin or other oral anticoagulants, due to a possible decrease or increase of their antithrombotic effect
Furosemide, oral anticoagulants
Furosemide enhances the effect of oral anticoagulant agent
Fusidic acid, oral anticoagulants
The co-administration with fusidate systemically may increase the plasma concentration of the anticoagulant.
Gemfibrozil [1], oral anticoagulants ---> SmPC of [1] of eMC
Gemfibrozil may potentiate the effects of oral anticoagulants, which necessitates careful monitoring of the anticoagulant dosing
Gentamicin, oral anticoagulants ---> SmPC of [imipenem/cilastatin] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Glibenclamide [1], oral anticoagulants ---> SmPC of [1] of EMA
Highly protein-bound medicinal products, which may also potentiate the hypoglycaemic action of glibenclamide due to glibenclamide displacement from plasma proteins
Glutethimide, oral anticoagulants
Glutethimide, enzymatic inductor, may increase the metabolism of the oral anticoagulant and decrease its plasma levels and effect
Griseofulvin, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Heparin, oral anticoagulants ---> SmPC of [sodium heparin] of eMC
It is considered unsafe to take NSAIDs in combination with anticoagulants due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
Hydantoins, oral anticoagulants
The hydantoin may weaken the effect of oral anticoagulant
Idarubicin [1], oral anticoagulants ---> SmPC of [1] of eMC
At combination of oral anticoagulants and anticancer chemotherapy, increased frequency of the INR (International Normalised Ratio) monitoring is recommended, since the risk for an interaction cannot be excluded.
Ifosfamide, oral anticoagulants
The co-administration may increase the risk of bleeding
Indobufen, oral anticoagulants
Indobufen can displace the anticoagulant from its plasma protein binding and increase its effects
Kebuzone, oral anticoagulants
The co-administration may enhance the effects and increase the bleeding risk
Lornoxicam, oral anticoagulants
The NSAID may enhance the effects of anticoagulant agent
Lumiracoxib, oral anticoagulants
Lumiracoxib may enhance the effects of anticoagulant agent
Lymecycline, oral anticoagulants [2] ---> SmPC of [2] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Macrolide antibiotics, oral anticoagulants ---> SmPC of [moxifloxacin] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Magaldrate, oral anticoagulants
Decreased absorption of oral anticoagulant. It is recommended to administer the two substances at least 2-3 hours apart.
Meloxicam, oral anticoagulants
Increased risk of bleeding due to inhibition of the platelet function. The combination of NSAID with oral anticoagulants is not recommended
Memantin [1], oral anticoagulants ---> SmPC of [1] of EMA
Close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants.
Meprobamate, oral anticoagulants [2] ---> SmPC of [2] of eMC
Like barbiturates, meprobamate can cause induction of liver enzymes, so that the availability and blood levels of drugs given concurrently that are metabolised in the liver may be affected.
Mercaptopurine [1], oral anticoagulants ---> SmPC of [1] of EMA
Inhibition of the anticoagulant effect of warfarin, when given with 6 -mercaptopurine, has been reported. Monitoring of the INR (International Normalised Ratio) value is recommended during concomitant administration with oral anticoagulants.
Meropenem [1], oral anticoagulants ---> SmPC of [1] of eMC
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Methoxsalen, oral anticoagulants
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Methylprednisolone [1], oral anticoagulants ---> SmPC of [1] of eMC
The efficacy of coumarins may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.
Metolazone, oral anticoagulants
The co-administration may prolong the bleeding time
Metronidazole [1], oral anticoagulants ---> SmPC of [1] of eMC
Some potentiation of anticoagulant therapy has been reported when metronidazole has been used with the warfarin type oral anticoagulants.
Mezlocillin, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Miconazole, oral anticoagulants
The co-administration is contraindicated. Unpredictable bleedings
Minocycline, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Moxifloxacin [1], oral anticoagulants ---> SmPC of [1] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Nadroparin, oral anticoagulants
Nadroparin should be used with caution by patients treated with oral anticoagulants
Nandrolone, oral anticoagulants
Anabolic steroids have been reported to increase the activity of oral anticoagulants.
Naproxen/esomeprazole [1], oral anticoagulants ---> SmPC of [1] of eMC
NSAIDs may enhance the effects of oral anti-coagulants (e.g. warfarin, dicoumarol)
Narcotine, oral anticoagulants
Noscapine may enhance the effect of oral anticoagulants of the type coumarine
Neomycin, oral anticoagulants
There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.
Norfloxacin, oral anticoagulants
The co-administration may enhance the effect of oral anticoagulant
NSAID, oral anticoagulants ---> SmPC of [flurbiprofen] of eMC
NSAIDs may enhance the effects of anticoagulants such as warfarin
Omega-3-acid ethyl ester, oral anticoagulants
Moderate increase in bleeding time
Opipramol, oral anticoagulants
The tricyclic antidepressant may potentiate the anti-coagulant effect
Oral anticoagulants [1], phenylbutazone ---> SmPC of [1] of eMC
NSAIDs may enhance the effects of oral anti-coagulants (e.g. warfarin, dicoumarol)
Oral anticoagulants, oral contraceptives ---> SmPC of [cyproterone/ethinylestradiol] of eMC
Oral contraceptives may decrease the effect of oral anticoagulants probably due to an antagonist effect on some coagulation factors
Oral anticoagulants, orlistat [2] ---> SmPC of [2] of EMA
When warfarin or other anticoagulants are given in combination with orlistat, international normalized ratio (INR) values should be monitored
Oral anticoagulants, ornidazole
Ornidazole enhances the anticoagulant effect
Oral anticoagulants, oxandrolone
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, paracetamol
The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.
Oral anticoagulants, parnaparin
The co-administration may cause a mutual enhancement of the anticoagulant effect
Oral anticoagulants, paroxetine [2] ---> SmPC of [2] of eMC
Concomitant use of paroxetine and oral anticoagulants can lead to an increased anticoagulant activity and haemorrhagic risk. Therefore, paroxetine should be used with caution in patients who are treated with oral anticoagulants.
Oral anticoagulants, pefloxacine
Close monitoring of the prothrombin time is recommended when administering pefloxacin with oral anticoagulants
Oral anticoagulants, pemetrexed [2] ---> SmPC of [2] of EMA
Patients treated with anticoagulant and antineoplastic agents should be monitored more frequently
Oral anticoagulants, pentoxifylline
The co-administration may increase the anticoagulant effect
Oral anticoagulants, phenobarbital
Phenobarbital, enzymatic inductor, may increase the metabolism of oral anticoagulant and decrease its plasma levels and effect
Oral anticoagulants, phenytoin [2] ---> SmPC of [2] of eMC
Oral anticoagulants may increase phenytoin serum levels
Oral anticoagulants, phytomenadione
The co-administration may decrease or abolish the anticoagulant effect
Oral anticoagulants, piperacillin
During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system, appropriate coagulation tests should be performed more frequently and monitored regularly.
Oral anticoagulants, piperacillin/tazobactam [2] ---> SmPC of [2] of eMC
During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system, appropriate coagulation tests should be performed more frequently and monitored regularly.
Oral anticoagulants, prednisolone
The anticoagulant effect may increase or decrease
Oral anticoagulants, prednisone [2] ---> SmPC of [2] of eMC
The efficacy of coumarin anticoagulants may be reduced or enhanced.
Oral anticoagulants, proglumetacine
The NSAID may enhance the effects of anticoagulant agent
Oral anticoagulants, propafenone [2] ---> SmPC of [2] of eMC
Propafenone has been shown to increase the plasma levels of oral anticoagulants (e.g. warfarin), with an accompanying increase in prothrombin time, which may require a reduction in the dose of oral anticoagulants.
Oral anticoagulants, prulifloxacin
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, pyrazolones
The co-administration may cause interactions
Oral anticoagulants, quinidine
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, quinine
Quinine may cause hypoprothrombinaemia and enhance the effects of anticoagulants.
Oral anticoagulants, quinolones ---> SmPC of [moxifloxacin] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Oral anticoagulants, reteplase [2] ---> SmPC of [2] of EMA
Caution should be employed when used reteplase with other medicinal products affecting haemostasis
Oral anticoagulants, retinol
Possibly increased anticoagulant effect and risk of bleeding
Oral anticoagulants, reviparin
Caution is recommended when coadministering reviparin with oral anticoagulants
Oral anticoagulants, salicylates ---> SmPC of [acetylsalicylic acid] of eMC
Displacement of oral anticoagulants from their plasma protein binding sites
Oral anticoagulants, saquinavir
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, SSRI ---> SmPC of [paroxetine] of eMC
Caution is advised in patients taking SSRIs, concomitantly with oral anticoagulants, drugs known to affect platelet function or increase risk of bleeding
Oral anticoagulants, streptokinase [2] ---> SmPC of [2] of eMC
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
Oral anticoagulants, streptokinase/streptodornase
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
Oral anticoagulants, sucralfate
Decreased absorption of orale anticoagulants cannot be precluded
Oral anticoagulants, sulfacetamide
The co-administration may enhance the anticoagulant effect and increase the bleeding risk. Special caution is recommended
Oral anticoagulants, sulfasalazine
The co-administration may enhance the anticoagulant effect and increase the bleeding risk. Special caution is recommended
Oral anticoagulants, sulindac
Possible increase of anticoagulant effect due to displacement from plasma proteins
Oral anticoagulants, sulphamides
The co-administration may enhance the anticoagulant effect and increase the bleeding risk. Special caution is recommended
Oral anticoagulants, sulphonamides
The co-administration may enhance the anticoagulant effect and increase the bleeding risk. Special caution is recommended
Oral anticoagulants, tacrolimus [2] ---> SmPC of [2] of EMA
Tacrolimus is extensively bound to plasma proteins. Possible interactions with other active substances known to have high affinity for plasma proteins should be considered
Oral anticoagulants, telithromycin [2] ---> SmPC of [2] of EMA
Increased anticoagulant activity has been reported in patients simultaneously treated with anticoagulants and antibiotics, including telithromycin.
Oral anticoagulants, testolactone
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, testosterone undecanoate
High doses of androgens may enhance the anticoagulant action of coumarine type agents and additional monitoring of INR and adjustment of anticoagulant dose may need to be considered.
Oral anticoagulants, testosterone [2] ---> SmPC of [2] of EMA
When testosterone is given concomitantly with anticoagulants, the anticoagulant effect may increase.
Oral anticoagulants, tetracyclines ---> SmPC of [moxifloxacin] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Oral anticoagulants, thiouracil
The co-administration may decrease the anticoagulant effect
Oral anticoagulants, thyroid hormones
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, ticagrelor [2] ---> SmPC of [2] of EMA
Ticagrelor should be used with caution with medicinal products that may increase the risk of bleeding
Oral anticoagulants, ticlopidine
Increased bleeding risk (combination of the anticoagulant and platelet aggregation inhibitor effect)
Oral anticoagulants, tinidazole
Drugs of similar chemical structure have been shown to potentiate the effects of oral anticoagulants.
Oral anticoagulants, tirofiban [2] ---> SmPC of [2] of eMC
Concurrent use of tirofiban with drugs that increase the risk of bleeding to a relevant degree is not recommended
Oral anticoagulants, tisopurine
Tisopurine may increase the anticoagulant effect
Oral anticoagulants, triamcinolone acetonide
Corticosteroids may potentiate or decrease anticoagulant action. Patients receiving oral anticoagulants and corticosteroids should therefore be closely monitored.
Oral anticoagulants, triamcinolone [2] ---> SmPC of [2] of eMC
Corticosteroids may potentiate or decrease anticoagulant action. Patients receiving oral anticoagulants and corticosteroids should therefore be closely monitored.
Oral anticoagulants, triamterene/hydrochlorothiazide
The co-administration of triamterene/hydrochlorothiazide may weaken the effect of oral anticoagulants or insulin
Oral anticoagulants, tricyclic antidepressant
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, trifluoperazine [2] ---> SmPC of [2] of eMC
Trifluoperazine may diminish the effect of oral anticoagulants.
Oral anticoagulants, trimethoprim/sulfamethoxazol ---> SmPC of [moxifloxacin] of eMC
A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins.
Oral anticoagulants, urokinase [2] ---> SmPC of [2] of eMC
Oral anticoagulants or heparin may increase the risk of haemorrhage and should not be used concomitantly with urokinase.
Oral anticoagulants, valdecoxib
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral anticoagulants, vitamin A
Possibly increased anticoagulant effect and risk of bleeding
Oral anticoagulants, vitamin C ---> SmPC of [ascorbic acid] of eMC
The action of oral anticoagulant may be modified by the ascorbic acid
Oral anticoagulants, vitamin K
The co-administration may decrease or abolish the anticoagulant effect
Oral anticoagulants, vorapaxar [2] ---> SmPC of [2] of EMA
When vorapaxar was co-administered with warfarin, there were no alterations in the pharmacokinetics/pharmacodynamics of warfarin. The coadministration of vorapaxar with anticoagulants e.g., warfarin and new oral anticoagulants (NOACs), should be avoided.
Oral anticoagulants, vortioxetine [2] ---> SmPC of [2] of EMA
Caution should be exercised when vortioxetine is combined with oral anticoagulants or antiplatelet medicinal products due to a potential increased risk of bleeding
Oral anticoagulants, warfarin
Increased anticoagulant activity. More frequent monitoring of prothrombin time/INR values should be considered
Oral anticoagulants, zafirlukast
The co-administration of zafirlukast with oral anticoagulants is contraindicated